Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.
Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P. Correale P, et al. Among authors: rotundo ms. J Immunother. 2014 Jan;37(1):26-35. doi: 10.1097/CJI.0000000000000004. J Immunother. 2014. PMID: 24316553 Clinical Trial.
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).
Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, Cusi MG, Tassone P, Francini G. Correale P, et al. Among authors: rotundo ms. Clin Cancer Res. 2008 Jul 1;14(13):4192-9. doi: 10.1158/1078-0432.CCR-07-5278. Clin Cancer Res. 2008. PMID: 18593999 Clinical Trial.
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L, Tassone P, Francini G, Tagliaferri P. Correale P, et al. Among authors: rotundo ms. J Immunother. 2010 May;33(4):435-41. doi: 10.1097/CJI.0b013e3181d32f01. J Immunother. 2010. PMID: 20386463 Free PMC article. Clinical Trial.
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
Correale P, Tindara Miano S, Remondo C, Migali C, Rotundo MS, Macrì P, Tagliaferri P, Caraglia M, Gotti G, Francini G. Correale P, et al. Among authors: rotundo ms. Cancer Biol Ther. 2009 Mar 15;8(6):497-502. doi: 10.4161/cbt.8.6.7593. Epub 2009 Mar 15. Cancer Biol Ther. 2009. PMID: 19242101 Free article. Clinical Trial.
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G. Correale P, et al. Among authors: rotundo ms. Cancer Biol Ther. 2010 May 1;9(9):685-93. doi: 10.4161/cbt.9.9.11441. Cancer Biol Ther. 2010. PMID: 20697196 Free article. Clinical Trial.
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients.
Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, Romano O, Abbruzzese A, Lamberti M, Luzzi L, Gotti G, Rotundo MS, Caraglia M, Tagliaferri P. Correale P, et al. Among authors: rotundo ms. Cancer Biol Ther. 2011 Jul 15;12(2):112-8. doi: 10.4161/cbt.12.2.15722. Epub 2011 Jul 15. Cancer Biol Ther. 2011. PMID: 21525780 Free article. Clinical Trial.
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma.
Correale P, Rotundo MS, Botta C, Del Vecchio MT, Ginanneschi C, Licchetta A, Conca R, Apollinari S, De Luca F, Tassone P, Tagliaferri P. Correale P, et al. Among authors: rotundo ms. Clin Cancer Res. 2012 Feb 1;18(3):850-7. doi: 10.1158/1078-0432.CCR-10-3186. Epub 2011 Dec 5. Clin Cancer Res. 2012. PMID: 22142823 Clinical Trial.
Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Rotundo MS, Ciliberto D, Tomaino V, Fabiani F, Talarico D, Sperlongano P, Doldo P, Cannataro M, Caraglia M, Tassone P, Tagliaferri P. Di Martino MT, et al. Among authors: rotundo ms. Cancer Biol Ther. 2011 Nov 1;12(9):780-7. doi: 10.4161/cbt.12.9.17781. Epub 2011 Nov 1. Cancer Biol Ther. 2011. PMID: 21892003 Free article.
14 results